Fifth Annual Clinical Advances in the Diagnosis and Management of Pulmonary Hypertension
Pulmonary hypertension (PH) is a common and widely misunderstood syndrome that results from a surprisingly large number of disease processes. It can occur at any age and the risk of developing PH increases with age and other medical conditions. Great strides have been made in the past 15 years in diagnosing and treating pulmonary arterial hypertension (PAH) so that the natural history of PAH is rapidly changing. On the other hand, the more common clinical variant, pulmonary venous hypertension (PVH) has been largely unaffected by medical therapy. In addition, there is often a divide between those whose treat PAH and those clinicians whose patients have PVH and are frustrated by the lack of effective therapy.
After attending this live activity, participants should be able to:
- Describe the epidemiology and pathophysiology of pulmonary hypertension.
- Determine who is at risk for pulmonary hypertension and effectively diagnose patients.
- Recognize the difference between PAH and PVH and how this translates into therapy.
- Outline the current approach to pulmonary hypertension treatment in the presence of related or underlying diseases.
- Evaluate current pharmacologic and medical management strategies for patients with pulmonary hypertension.
- Incorporate novel therapies into patient care for improved outcomes.
- Identify when to refer patients for specialty treatment.
Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
For more information please visit the official event page.
Click HERE to view the syllabus